Barometer Capital Management Inc. Has $2.03 Million Holdings in Axon Enterprise, Inc $AXON

Barometer Capital Management Inc. lessened its position in Axon Enterprise, Inc (NASDAQ:AXON) by 58.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,832 shares of the biotechnology company’s stock after selling 3,954 shares during the quarter. Barometer Capital Management Inc.’s holdings in Axon Enterprise were worth $2,032,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AXON. Newbridge Financial Services Group Inc. boosted its position in shares of Axon Enterprise by 2.8% in the second quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock worth $421,000 after buying an additional 14 shares during the period. Vicus Capital lifted its stake in Axon Enterprise by 3.7% in the 3rd quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 14 shares in the last quarter. Evergreen Capital Management LLC lifted its stake in Axon Enterprise by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after acquiring an additional 15 shares in the last quarter. Blue Trust Inc. boosted its position in Axon Enterprise by 2.5% during the 3rd quarter. Blue Trust Inc. now owns 645 shares of the biotechnology company’s stock worth $463,000 after acquiring an additional 16 shares during the period. Finally, NorthCrest Asset Manangement LLC grew its stake in Axon Enterprise by 5.4% during the 3rd quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 16 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Recent operating momentum and scale: company commentary and filings highlighted robust device and software demand, rising ARR/bookings and accelerating revenue that underpinned the prior rally. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Positive Sentiment: Analyst backing and price-target runway: multiple firms maintain buy/overweight ratings and the median 6‑month target sits well above current levels, giving upside for longer-term holders. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Positive Sentiment: Momentum recap: AXON had climbed nearly 29% over the prior month on strong device/software demand — a factor that supports the bull case if execution continues. Axon Stock Rises 28.6% in a Month: Should Investors Buy or Wait?
• Neutral Sentiment: No meaningful short-interest signal (data shows zero or NaN) — likely a reporting anomaly, so it shouldn’t be interpreted as a fresh bearish catalyst.
• Neutral Sentiment: Third‑party/industry headlines referencing “Axon” (e.g., AppLovin’s “Axon by AppLovin” product and related studies) are unrelated to Axon Enterprise’s business and can confuse coverage — treat those items as industry noise. AppLovin (APP) Is Up 19.5% After Showcasing AXON 2.0 And AI E-commerce Pivot
• Negative Sentiment: Profit‑taking and valuation sensitivity: analysts and market commentary point to a classic post‑earnings retracement after a fast run; high valuation metrics make the stock susceptible to short‑term pullbacks. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Negative Sentiment: Heavy insider selling noted in recent disclosures increases near‑term perceived risk and can sap sentiment even if proceeds are routine. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Negative Sentiment: Relative underperformance vs. peers on the day added selling pressure, suggesting short‑term rotation rather than a fresh fundamental shift. Axon Enterprise Inc. stock underperforms Tuesday when compared to competitors

Axon Enterprise Price Performance

NASDAQ AXON opened at $517.57 on Thursday. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $41.61 billion, a PE ratio of 340.51, a price-to-earnings-growth ratio of 11.31 and a beta of 1.46. Axon Enterprise, Inc has a 12-month low of $396.41 and a 12-month high of $885.91. The company has a 50 day moving average price of $533.80 and a two-hundred day moving average price of $613.08.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, topping the consensus estimate of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The company had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. During the same quarter in the prior year, the business posted $2.08 EPS. Axon Enterprise’s quarterly revenue was up 38.5% on a year-over-year basis. As a group, equities analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $500.24, for a total transaction of $5,002,400.00. Following the transaction, the chief executive officer owned 3,090,997 shares of the company’s stock, valued at approximately $1,546,240,339.28. This represents a 0.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Isaiah Fields sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $535.01, for a total value of $1,070,020.00. Following the completion of the transaction, the insider directly owned 55,588 shares in the company, valued at $29,740,135.88. The trade was a 3.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 24,634 shares of company stock valued at $13,803,095 over the last three months. 4.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have recently issued reports on AXON shares. Royal Bank Of Canada reduced their price target on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a research report on Wednesday, February 25th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday, December 29th. Robert W. Baird set a $800.00 target price on shares of Axon Enterprise in a research report on Wednesday, February 25th. UBS Group lowered their price target on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Finally, Wall Street Zen raised shares of Axon Enterprise from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $762.93.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.